To hear about similar clinical trials, please enter your email below
Trial Title:
PDL1 In Primary Colorectal Carcinoma and Its Prognostic Impact
NCT ID:
NCT05692895
Condition:
PDL1- Colorectal Carcinoma
Conditions: Official terms:
Carcinoma
Colorectal Neoplasms
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Retrospective
Summary:
Colorectal cancer (CRC) is a highly heterogenous disease. It the third most commonly
diagnosed cancer in the world and the second cause of death among cancer cases mortality.
Its incidence is rising all over the world, especially in developing countries . In Egypt
it is coming the seventh cancer in incidence according to World Health Organization (WHO,
2020). Although there is much improvement in the diagnosis and treatment, but CRC is
still constituting a big impact on human life and health, so researchers are trying to
find out new therapeutic targets .
Programmed cell death protein 1 (PD-1) is an inhibitory receptor which is expressed on
the surface of T lymphocytes during activation. Its role is to control T cell effector
activity for various cellular responses as infections, autoimmune reactions, and cancer .
Cancer cells develop PD-ligand1 (PD-L1) expression which is a transmembrane molecule
belonging to B7 family. Its action is through PD-1/PD-L1 reaction, and causing invasion
and metastasis of cancer cells by protecting it from immunosurveillance by inhibiting T
cell effector function, leading to carcinogenesis and development of many cancers
including colorectal cancer.
Criteria for eligibility:
Study pop:
A retrospective study will be carried out on 60 colorectal carcinoma specimens that were
collected randomly from archives of Pathology Department, Faculty of Medicine, Sohag
University
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
1. Both endoscopic and excisional biopsy specimens.
2. All the studied cases include sufficient materials for the immunohistochemical
study.
3. Complete clinical data
Exclusion Criteria:
1. Patients with recurrence of the primary tumor.
2. Patients with a history of preoperative chemotherapy and/or radiotherapy.
3. Insufficient or tiny tissue biopsies
Gender:
All
Minimum age:
20 Years
Maximum age:
90 Years
Healthy volunteers:
No
Start date:
February 2023
Completion date:
July 2023
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05692895
